All Posts

The Canadian cannabis industry has entered a new phase of maturation since its federal legalization. This phase is marked by heightened regulatory scrutiny and an increasing focus on consumer safety. For cannabis licence holders, especially small and medium-sized enterprises (SMEs), navigating the complex requirements for post-market surveillance and adverse event (AE) reporting is a significant challenge. Non-compliance with Health Canada's regulations can expose businesses